Candida auris: The Fungal Superbug Reshaping Healthcare EVS Protocols

Candida auris (C. auris) has rapidly emerged as one of the most serious and difficult-to-control pathogens in healthcare settings. First identified in 2009, this multidrug-resistant fungus has spread to healthcare facilities across more than 50 countries, and the CDC has classified it as an Urgent Threat, its highest level of concern.

For environmental services teams, C. auris presents a challenge unlike most bacterial pathogens: it is extraordinarily persistent on surfaces, resistant to many standard disinfectants, and capable of causing serious bloodstream infections in vulnerable patients.

Why C. auris Is Different

Most healthcare-associated pathogens are susceptible to routine EPA-registered disinfectants when used correctly. C. auris is not. Studies have shown that it can survive on dry surfaces including bed rails, IV poles, call buttons, and medical equipment for weeks to months. It also demonstrates resistance to several classes of antifungal medications, making infections extremely difficult to treat once established.

Key characteristics that make C. auris a unique EVS challenge:

• Surface persistence: C. auris can survive on plastic and stainless steel surfaces for up to 14 days or longer under dry conditions.
• Disinfectant resistance: Quaternary ammonium compounds (quats), the most widely used disinfectants in healthcare, have demonstrated limited efficacy against C. auris.
• Asymptomatic colonization: Patients can carry C. auris on their skin without showing symptoms, silently contaminating surfaces throughout their stay.
• Outbreak potential: Once introduced into a facility, C. auris can spread rapidly through environmental contamination, particularly in ICUs and long-term care settings.

What Standard Cleaning Protocols Miss

The most critical gap in standard EVS protocols when it comes to C. auris is disinfectant selection. Many facilities rely on quaternary ammonium-based products as their primary surface disinfectant, and while these products are effective against a broad range of bacteria and viruses, they are not reliably effective against C. auris.

The CDC and EPA recommend the following disinfectant classes for C. auris decontamination:

• Sodium hypochlorite (bleach-based products) | EPA-registered bleach disinfectants at appropriate concentrations (1,000 to 5,000 ppm) are among the most effective agents against C. auris on hard surfaces.
• Accelerated hydrogen peroxide (AHP) | AHP-based products with demonstrated C. auris efficacy on the EPA List P are an effective alternative where bleach is not appropriate.
• EPA List P products | The EPA maintains a specific list of disinfectants with demonstrated efficacy against C. auris. Facilities should verify their products appear on this list.

Equally important is contact time. Even effective disinfectants fail when surfaces are not kept visibly wet for the full manufacturer-specified dwell time, a step that is routinely rushed in high-turnover environments.

EVS Protocols for C. auris Containment

When C. auris is identified or suspected in a facility, EVS protocols must be escalated immediately. The following measures are recommended by the CDC and APIC:

• Enhanced terminal cleaning of all rooms occupied by confirmed or suspected C. auris patients, using EPA List P disinfectants with full contact time compliance.
• Daily enhanced cleaning of high-touch surfaces in rooms with colonized or infected patients, not just terminal cleaning at discharge.
• UV-C adjunct disinfection following manual cleaning to provide a validated no-touch layer of decontamination, particularly in high-risk zones.
• Dedicated equipment — cleaning equipment used in C. auris rooms should not be shared with other patient areas without thorough decontamination.
• Staff PPE and hand hygiene — EVS staff should wear gloves and gowns when cleaning C. auris rooms, and perform hand hygiene with soap and water (not just alcohol-based hand rub) upon exit.
• Documented cleaning logs — every cleaning event in a C. auris room should be logged with product used, concentration, contact time, and staff member, to support infection prevention investigations.

The Role of ATP Testing in C. auris Response

ATP bioluminescence testing — which measures organic residue on surfaces as a proxy for cleanliness — is a valuable tool for verifying cleaning efficacy in C. auris response situations. While ATP testing does not specifically detect C. auris, it provides real-time feedback on whether surfaces have been adequately cleaned and disinfected, allowing EVS supervisors to identify and correct deficiencies before the next patient occupies the room.

PremierCare incorporates ATP surface verification into our standard quality assurance program — and escalates to enhanced ATP monitoring protocols during any C. auris response event.

How PremierCare Addresses C. auris

PremierCare Environmental Services maintains C. auris-specific response protocols as part of our standard infection prevention program. Our EVS supervisors are trained to recognize C. auris alert notifications from infection prevention staff and immediately activate enhanced cleaning protocols — including EPA List P disinfectant deployment, extended contact time verification, and UV-C adjunct disinfection.

We work directly with your facility's infection preventionist to ensure our environmental response is coordinated with clinical containment measures — because controlling C. auris requires a team approach where EVS and clinical staff operate from the same playbook.

If your facility has identified C. auris or wants to assess your current environmental cleaning protocols for C. auris readiness, contact PremierCare to schedule a facility assessment.